Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
Conradi LC, Spitzner M, Metzger AL, Kisly M, Middel P, Bohnenberger H, Gaedcke J, Ghadimi MB, Liersch T, Rüschoff J, Beißbarth T, König A, Grade M.
Conradi LC, et al. Among authors: grade m.
BMC Cancer. 2019 Sep 5;19(1):880. doi: 10.1186/s12885-019-6051-0.
BMC Cancer. 2019.
PMID: 31488078
Free PMC article.